Journal of Clinical Oncology - ASCO Publications
WEBSep 9, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is …
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
WEBFor more information on these guidelines, including information about planned guidelines, please access the ASCO.org guidelines page. Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of approved medical ...
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
WEBOct 17, 2022 · Perioperative chemotherapy is recommended for a total preoperative and postoperative duration of 6 months, on the basis of total duration of chemotherapy in the EORTC 40983 trial. 64. Table 10. Perioperative Chemotherapy Versus Surgery Alone for Patients With Liver Metastases From Colorectal Cancer 22. Open in viewer.
Management of Stage III Non–Small-Cell Lung Cancer: ASCO …
WEBDec 22, 2021 · Introduction. The purpose of this guideline is to help clinicians involved in the diagnosis and treatment of lung cancer accurately confirm the presence of stage III non–small-cell lung cancer (NSCLC) and offer the most appropriate treatments.
Management of Immune-Related Adverse Events in Patients …
WEBImmunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that …
Recent Advances in the Management of Metastatic Prostate Cancer
WEBIn 2021, it is estimated that 26% of new noncutaneous cancer cases will be because of prostate cancer resulting in 11% of cancer-related deaths in the United States, making it the most common malignancy in men and the second leading cause of cancer mortality. 1 Following onset of metastatic disease, the disease is invariably fatal with a 5-year …
Prevention and Management of Chemotherapy-Induced …
WEBJul 14, 2020 · The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged.Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who …
Management of Cancer Therapy–Associated Oral Mucositis
WEBAbstract. Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by uncontrolled ...
Survival in Patients With Brain Metastases: Summary Report on the ...
WEBSep 15, 2020 · Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation (P < .01) between subgroups.Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain …
Updated Diagnostic Criteria and Staging System for Multiple …
WEBMay 19, 2016 · The diagnosis of MM requires 10% or more clonal plasma cells on bone marrow examination or a biopsy-proven plasmacytoma plus the presence of one or more myeloma-defining events. 10 Myeloma-defining events include the presence of one or more CRAB features, or one or more biomarkers of malignancy. The three biomarkers …